Coloplast is absolutely a high-quality med-tech growth story and is worthy of a premium. Unfortunately, even with an advantageous discount rate, the shares are not cheap on discounted cash flow.
Shares of Grail, a maker of early-detection cancer screening tests, soared last week. Here are the key chart levels to watch.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback